期刊文献+

ABCB1 C3435T基因多态性与新疆癫痫患儿左乙拉西坦血药浓度和临床疗效的相关性研究 被引量:3

Relationship between Multidrug Resistance Gene ABCB1 C3435T Gene Polymorphism and Serum Concentration of Levetiracetam in Children with Epilepsy in Xinjiang
原文传递
导出
摘要 目的初步探讨ABCB1 C3435T基因多态性是否影响新疆癫痫患儿口服左乙拉西坦(levetiracetam,LEV)后的血药浓度、临床疗效和不良反应。方法收集并测定116例口服LEV的新疆癫痫患儿血清药物浓度,采用聚合酶链反应-荧光染色原位杂交法检测其ABCB1 C3435T基因型,分析患儿ABCB1 C3435T基因多态性与其血药浓度、临床疗效与不良反应之间的相关性。结果患儿ABCB1 C3435T的C和T等位基因频率存在显著性差异(χ^2=12.520,P<0.01)。CC型、CT型和TT型患儿的血药浓度结果分别为12.02、13.74和14.53μg·mL^-1,方差分析结果显示,3组之间存在显著性差异(F=3.550,P<0.05)。携带TT型的新疆癫痫患儿LEV血药浓度明显高于CC型和CT型。CC型、CT型和TT型患儿的LEV治疗有效组和无效组的css差异均无统计学意义(P>0.05)。CT型患儿的临床治疗有效率高于CC型和TT型患儿,TT型患儿的不良反应发生率高于CC型和CT型患儿。CC型、CT型和TT型患儿的临床疗效和不良反应存在显著性差异(χ^2=12.870,P<0.01;χ^2=19.292,P<0.01)。结论ABCB1 C3435T基因多态性可能影响新疆癫痫患儿的LEV血药浓度结果、临床疗效和不良反应。 OBJECTIVE To explore the relationship between multidrug resistance gene ABCB1 C3435T gene polymorphism and serum concentration,clinical efficacy and adverse reactions of levetiracetam(LEV)in children with epilepsy in Xinjiang.METHODS The serum concentration of 116 children with epilepsy of in Xinjiang were collected and determined by oral LEV.The ABCB1 C3435T genotype was detected by polymerase chain reaction-fluorescence staining in situ hybridization.The correlation between ABCB1 C3435T gene polymorphism and serum concentration,clinical efficacy and adverse reactions was analyzed.RESULTS The C and T allele frequencies of ABCB1 C3435T in children were significantly different(χ^2=12.520,P<0.01).The serum concentration of CC,CT and TT genotypes were 12.02,13.74 and 14.53μg·mL^-1,respectively.The results of ANOVA showed that there were significant differences among the three groups(F=3.550,P<0.05).The serum concentration of LEV in children with epilepsy in Xinjiang with TT type was significantly higher than that of CC type and CT type.There was no significant difference in css between LEV effective group and ineffective group in CC type,CT type and TT type(P>0.05).The clinical effective rate of CT type was higher than that of CC type and TT type,and the incidence of adverse reactions of TT type was higher than that of CC type and CT type.There were significant differences in clinical efficacy and adverse reactions among CC type,CT type and TT type(χ^2=12.870,P<0.01;χ^2=19.292,P<0.01).CONCLUSION ABCB1 C3435T gene polymorphism may has a effect on the serum concentration,clinical efficacy and adverse reactions of LEV in children with epilepsy in Xinjiang.
作者 赵婷 于静 王婷婷 冯杰 孙力 孙岩 于鲁海 李红健 ZHAO Ting;YU Jing;WANG Ting-ting;FENG Jie;SUN Li;SUN Yan;YU Lu-hai;LI Hong-jian(Department of Pharmacy,People′s Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China;Department of Neurology,Children′s Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2020年第18期1530-1534,共5页 Chinese Pharmaceutical Journal
基金 中国抗癫痫协会癫痫科研基金-优时比基金项目资助(201804)。
关键词 ABCB1 C3435T 血药浓度 左乙拉西坦 ABCB1 C3435T serum concentration levetiracetam
  • 相关文献

参考文献4

二级参考文献56

  • 1付永娟,朴月善,卢德宏.难治性癫的神经病理学特点[J].卒中与神经疾病,2006,13(1):62-64. 被引量:7
  • 2吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 3李劲梅,王学峰,肖飞,曾艳,林涛,席志芹.自身对照左乙拉西坦添加治疗耐药性癫痫部分性发作的疗效及安全性[J].中国新药与临床杂志,2007,26(5):381-384. 被引量:12
  • 4SAKAEDA T, NAKAMURA T, OKUMURA K. Pharmacogenetics of MDRI and its impact on the pharmacokinetics and pharmacodynamics of drugs [ J ]. Pharmacogelmmics, 2003,4 ( 4 ) : 397- 410.
  • 5BECQUEMONT L, VERSTUYIFYF C, KERB R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans [J]. Clin Pharmacol Ther, 2001,70 ( 4 ) : 3 l 1-316.
  • 6VON AHSEN N, RICHTER M, GRUPP C, et al. No influence of the MDR-l C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporine A trough concentrations or rejection incidence in stable renal transplant recipients[J]. Clin Chem, 2001,47(6) :1048-1052.
  • 7MIND I, ELLINGIROD V L C3435T mutation in exon 26 of the human MDRI gene and cyclosporine harmacokinetics in healthy subiectsl pJ]. Ther Drug Monit, 2002, 24(3) :400-404.
  • 8VERSTUYFT C, STRABACH S, EL-MORABET H, et al. Dipy- ridamole enhances digoxin bioavailability via P-gtycoprotein inhibition [ J ]. Clin Pharmacol Ther,2003, 73 ( 1 ) :51-60.
  • 9TANABE M, IEIRI I, NAGATA N, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the muhidmg resistance (MDR) -l gene [ J ]. J Pharmacol Exp Ther, 2001, 297(3):1137-1143.
  • 10JOHNE A, KOPKE K, GERLOFF T, et al. Modulation of steadystate kinetics of digoxin by haplotypes of the P-glycoprotein MDRI gene[J]. Clin Pharmacol Ther,2002, 72(5) : 584-594.

共引文献28

同被引文献12

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部